Dune Medical Devices taps into the Southeast medtech ecosystem to expand its radiofrequency (RF) Spectroscopy device portfolio
Dune Medical Devices, makers of MarginProbe, announced today the company will relocate their U.S. headquarters to Alpharetta (Atlanta), Georgia. According to Dune Medical CEO Lori Chmura the move from Paoli, Pennsylvania to Atlanta will help accomplish key strategic initiatives including clinical uptake and reimbursement for MarginProbe as well as the expansion of the company’s cancer detection device portfolio.
“Atlanta’s high concentration of hospitals, engineers and medtech infrastructure will support MarginProbe’s march to standard of care status for breast cancer lumpectomy candidates as well as the efficient development and commercialization of other applications of our RF Spectroscopy platform,” says Dune Medical CEO Lori Chmura.
Dune Medical Devices’ proprietary tissue characterization technology, Radiofrequency (RF) Spectroscopy, helps surgeons in the operating room identify microscopic residual cancer at the surgical margin. This technology will be applied to a variety of cancers inclusive of the biopsy market as well. The MarginProbe System for use in breast cancer lumpectomy procedures, Dune’s first device to market, achieved FDA approval in 2013. It surpassed use in 10,000 cases earlier this year. The company recently announced a $12.3 million funding round.
“Dune’s proprietary technology is already demonstrating high value by improving outcomes and reducing overall costs,” said Tiffany Wilson, CEO of GCMI and it’s preclinical arm, T3 Labs. “Having a proven, commercialized, investable company like Dune Medical select Atlanta is a testament to the strength of our local and regional medtech ecosystem.”
According to Jason Rupp, executive director of the Southeastern Medical Device Association (SEMDA), 40 percent of investors surveyed during the organization’s 2017 flagship conference intend on investing more than $500,000 in medtech startups in the next 12 months, while more than 30 percent of those surveyed plan to make two or more investments within the same timeframe.
Chmura also expects Dune’s Atlanta relocation to expand the pool of candidates and applicants for open corporate positions including finance leadership.
About Dune Medical Devices
Imagine not having to wonder, did we get it all?
At Dune Medical Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. We do this by developing innovative tissue characterization technologies that make it possible for physicians to more consistently eliminate cancerous tissue in the first procedure- improving the cancer care experience. Our solutions, which are developed on a first-of-its kind RF Spectroscopy platform can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “did we get it all?”
Vice President, Healthcare
Write2Market for Dune Medical Devices
+1 (404) 414-4240